secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0001683168-23-008204
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech invests $5M in Femasys, expanding strategy to utilize $74.6M cash
--------------------------------------------------------------------------------

- PharmaCyte (PMCB) purchases $5M senior unsecured convertible notes from Femasys (FEMY) at 6% interest, maturing in 2 years.
- Notes convertible at $1.18/share; warrants to buy up to ~8.5M FEMY shares at $1.18 and $1.475 per share.
- Interim CEO Josh Silverman will join Femasys' Board of Directors; collaboration agreement for joint research.
- PharmaCyte had $74.6M cash as of July 31, 2023; investment marks first external tech deployment.
- Femasys offers women's health products including late-stage FemBloc and FDA-cleared FemaSeed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-008204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer